JP7637150B2 - 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 - Google Patents

神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 Download PDF

Info

Publication number
JP7637150B2
JP7637150B2 JP2022559518A JP2022559518A JP7637150B2 JP 7637150 B2 JP7637150 B2 JP 7637150B2 JP 2022559518 A JP2022559518 A JP 2022559518A JP 2022559518 A JP2022559518 A JP 2022559518A JP 7637150 B2 JP7637150 B2 JP 7637150B2
Authority
JP
Japan
Prior art keywords
dextromethorphan
bupropion
human
week
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559518A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021202419A5 (de
JP2023519965A (ja
Inventor
タビュトー、ヘリオット
Original Assignee
アンテシップ バイオベンチャーズ トゥー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/894,713 external-priority patent/US10898453B2/en
Application filed by アンテシップ バイオベンチャーズ トゥー エルエルシー filed Critical アンテシップ バイオベンチャーズ トゥー エルエルシー
Publication of JP2023519965A publication Critical patent/JP2023519965A/ja
Publication of JPWO2021202419A5 publication Critical patent/JPWO2021202419A5/ja
Priority to JP2024212992A priority Critical patent/JP2025032232A/ja
Application granted granted Critical
Publication of JP7637150B2 publication Critical patent/JP7637150B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022559518A 2020-03-30 2021-03-29 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 Active JP7637150B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024212992A JP2025032232A (ja) 2020-03-30 2024-12-06 アルツハイマー病に関連する焦燥を治療するための医薬

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063002132P 2020-03-30 2020-03-30
US63/002,132 2020-03-30
US202063016178P 2020-04-27 2020-04-27
US63/016,178 2020-04-27
US202063032517P 2020-05-29 2020-05-29
US63/032,517 2020-05-29
US202063032567P 2020-05-30 2020-05-30
US63/032,567 2020-05-30
US16/894,713 US10898453B2 (en) 2013-11-05 2020-06-05 Bupropion as a modulator of drug activity
US16/894,713 2020-06-05
PCT/US2021/024718 WO2021202419A1 (en) 2020-03-30 2021-03-29 Use of bupropion and dextromethorphan combinations for treating neurological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024212992A Division JP2025032232A (ja) 2020-03-30 2024-12-06 アルツハイマー病に関連する焦燥を治療するための医薬

Publications (3)

Publication Number Publication Date
JP2023519965A JP2023519965A (ja) 2023-05-15
JPWO2021202419A5 JPWO2021202419A5 (de) 2023-07-20
JP7637150B2 true JP7637150B2 (ja) 2025-02-27

Family

ID=77930161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559518A Active JP7637150B2 (ja) 2020-03-30 2021-03-29 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用
JP2024212992A Pending JP2025032232A (ja) 2020-03-30 2024-12-06 アルツハイマー病に関連する焦燥を治療するための医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024212992A Pending JP2025032232A (ja) 2020-03-30 2024-12-06 アルツハイマー病に関連する焦燥を治療するための医薬

Country Status (6)

Country Link
EP (1) EP4125837A4 (de)
JP (2) JP7637150B2 (de)
KR (1) KR20220161414A (de)
CN (1) CN115697314A (de)
CA (1) CA3179048A1 (de)
WO (1) WO2021202419A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
WO2022119981A1 (en) 2020-12-01 2022-06-09 Antecip Bioventures Ii Llc Bupropion and dextromethrophan for reduction of suicide risk in depression patients
AU2022316152A1 (en) * 2021-07-21 2024-02-01 Antecip Bioventures Ii Llc Treatment of depression
CN119212709A (zh) * 2022-05-17 2024-12-27 安泰赛普生物风投二代有限责任公司 抑郁的治疗
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
EP4626429A1 (de) * 2022-11-28 2025-10-08 Antecip Bioventures II LLC Bupropion als modulator der arzneimittelaktivität

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069809A1 (en) 2013-11-05 2015-05-14 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11273134B2 (en) * 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) * 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) * 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) * 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9763932B2 (en) * 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069809A1 (en) 2013-11-05 2015-05-14 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Axsome News Release, Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder，2019年12月16日，URL: https://axsometherapeuticsinc.gcs-web.com/node/8921/pdf
JAMA，2015年，Vol.314, No.12，p.1242-1254，doi:10.1001/jama.2015.10214
O'GORMAN, Cedric et al.，AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer's Disease，AAIC CONFERENCE，2018年，P2-033，URL: https://axsometherapeuticsinc.gcs-web.com/static-files/411eadec-47c6-43e1-aa48-f6ad6723345b

Also Published As

Publication number Publication date
CN115697314A (zh) 2023-02-03
KR20220161414A (ko) 2022-12-06
EP4125837A1 (de) 2023-02-08
WO2021202419A1 (en) 2021-10-07
EP4125837A4 (de) 2024-03-20
JP2023519965A (ja) 2023-05-15
JP2025032232A (ja) 2025-03-11
CA3179048A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7637150B2 (ja) 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用
US11524008B2 (en) Bupropion as a modulator of drug activity
US11419867B2 (en) Bupropion as a modulator of drug activity
US11571399B2 (en) Bupropion as a modulator of drug activity
US11497721B2 (en) Bupropion as a modulator of drug activity
US11617728B2 (en) Bupropion as a modulator of drug activity
US11285118B2 (en) Bupropion as a modulator of drug activity
US11596627B2 (en) Bupropion as a modulator of drug activity
US11433067B2 (en) Bupropion as a modulator of drug activity
US11382874B2 (en) Bupropion as a modulator of drug activity
US11534414B2 (en) Bupropion as a modulator of drug activity
US11510918B2 (en) Bupropion as a modulator of drug activity
US11617747B2 (en) Bupropion as a modulator of drug activity
US11571417B2 (en) Bupropion as a modulator of drug activity
US11439636B1 (en) Bupropion as a modulator of drug activity
US11357744B2 (en) Bupropion as a modulator of drug activity
US11191739B2 (en) Bupropion as a modulator of drug activity
US20250032432A1 (en) Bupropion as a modulator of drug activity
US11541021B2 (en) Bupropion as a modulator of drug activity
US10933034B2 (en) Bupropion as a modulator of drug activity
US11020389B2 (en) Bupropion as a modulator of drug activity
US10966941B2 (en) Bupropion as a modulator of drug activity
US10945973B2 (en) Bupropion as a modulator of drug activity
US20230277478A1 (en) Bupropion as a modulator of drug activity
US10898453B2 (en) Bupropion as a modulator of drug activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250214

R150 Certificate of patent or registration of utility model

Ref document number: 7637150

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150